PURPOSE: To investigate cancer treatment plus pathogenic germline mutations (PGMs) in DNA repair genes (DRGs) for identification of childhood cancer survivors at increased risk of subsequent neoplasms (SNs). METHODS: Whole-genome sequencing was performed on blood-derived DNA from survivors in the St Jude Lifetime Cohort. PGMs were evaluated in 127 genes from 6 major DNA repair pathways. Cumulative doses of chemotherapy and body region-specific radiotherapy (RT) were abstracted from medical records. Relative rates (RRs) and 95% CIs of SNs by mutation status were estimated using multivariable piecewise exponential models. RESULTS: Of 4,402 survivors, 495 (11.2%) developed 1,269 SNs. We identified 538 PGMs in 98 DRGs (POLG, MUTYH, ERCC2, and BRCA2, among others) in 508 (11.5%) survivors. Mutations in homologous recombination (HR) genes were significantly associated with an increased rate of subsequent female breast cancer (RR, 3.7; 95% CI, 1.8 to 7.7), especially among survivors with chest RT ≥ 20 Gy (RR, 4.4; 95% CI, 1.6 to 12.4), or with a cumulative dose of anthracyclines in the second or third tertile (RR, 4.4; 95% CI, 1.7 to 11.4). Mutations in HR genes were also associated with an increased rate of subsequent sarcoma among those who received alkylating agent doses in the third tertile (RR, 14.9; 95% CI, 4.0 to 38.0). Mutations in nucleotide excision repair genes were associated with subsequent thyroid cancer for those treated with neck RT ≥ 30 Gy (RR, 12.9; 95% CI, 1.6 to 46.6) with marginal statistical significance. CONCLUSION: Our study provides novel insights regarding the contribution of genetics, in combination with known treatment-related risks, for the development of SNs. These findings have the potential to facilitate identification of high-risk survivors who may benefit from genetic counseling and/or testing of DRGs, which may further inform personalized cancer surveillance and prevention strategies.
PURPOSE: To investigate cancer treatment plus pathogenic germline mutations (PGMs) in DNA repair genes (DRGs) for identification of childhood cancer survivors at increased risk of subsequent neoplasms (SNs). METHODS: Whole-genome sequencing was performed on blood-derived DNA from survivors in the St Jude Lifetime Cohort. PGMs were evaluated in 127 genes from 6 major DNA repair pathways. Cumulative doses of chemotherapy and body region-specific radiotherapy (RT) were abstracted from medical records. Relative rates (RRs) and 95% CIs of SNs by mutation status were estimated using multivariable piecewise exponential models. RESULTS: Of 4,402 survivors, 495 (11.2%) developed 1,269 SNs. We identified 538 PGMs in 98 DRGs (POLG, MUTYH, ERCC2, and BRCA2, among others) in 508 (11.5%) survivors. Mutations in homologous recombination (HR) genes were significantly associated with an increased rate of subsequent female breast cancer (RR, 3.7; 95% CI, 1.8 to 7.7), especially among survivors with chest RT ≥ 20 Gy (RR, 4.4; 95% CI, 1.6 to 12.4), or with a cumulative dose of anthracyclines in the second or third tertile (RR, 4.4; 95% CI, 1.7 to 11.4). Mutations in HR genes were also associated with an increased rate of subsequent sarcoma among those who received alkylating agent doses in the third tertile (RR, 14.9; 95% CI, 4.0 to 38.0). Mutations in nucleotide excision repair genes were associated with subsequent thyroid cancer for those treated with neck RT ≥ 30 Gy (RR, 12.9; 95% CI, 1.6 to 46.6) with marginal statistical significance. CONCLUSION: Our study provides novel insights regarding the contribution of genetics, in combination with known treatment-related risks, for the development of SNs. These findings have the potential to facilitate identification of high-risk survivors who may benefit from genetic counseling and/or testing of DRGs, which may further inform personalized cancer surveillance and prevention strategies.
Authors: Wendy Landier; Smita Bhatia; Debra A Eshelman; Katherine J Forte; Teresa Sweeney; Allison L Hester; Joan Darling; F Daniel Armstrong; Julie Blatt; Louis S Constine; Carolyn R Freeman; Debra L Friedman; Daniel M Green; Neyssa Marina; Anna T Meadows; Joseph P Neglia; Kevin C Oeffinger; Leslie L Robison; Kathleen S Ruccione; Charles A Sklar; Melissa M Hudson Journal: J Clin Oncol Date: 2004-12-02 Impact factor: 44.544
Authors: Ella R Thompson; Maria A Doyle; Georgina L Ryland; Simone M Rowley; David Y H Choong; Richard W Tothill; Heather Thorne; Daniel R Barnes; Jason Li; Jason Ellul; Gayle K Philip; Yoland C Antill; Paul A James; Alison H Trainer; Gillian Mitchell; Ian G Campbell Journal: PLoS Genet Date: 2012-09-27 Impact factor: 5.917
Authors: Marilyn Stovall; Sarah S Donaldson; Rita E Weathers; Leslie L Robison; Ann C Mertens; Jeanette Falck Winther; Jorgen H Olsen; John D Boice Journal: Int J Radiat Oncol Biol Phys Date: 2004-10-01 Impact factor: 8.013
Authors: Raphael Ceccaldi; Jessica C Liu; Ravindra Amunugama; Ildiko Hajdu; Benjamin Primack; Mark I R Petalcorin; Kevin W O'Connor; Panagiotis A Konstantinopoulos; Stephen J Elledge; Simon J Boulton; Timur Yusufzai; Alan D D'Andrea Journal: Nature Date: 2015-02-02 Impact factor: 69.504
Authors: Nickhill Bhakta; Qi Liu; Kirsten K Ness; Malek Baassiri; Hesham Eissa; Frederick Yeo; Wassim Chemaitilly; Matthew J Ehrhardt; Johnnie Bass; Michael W Bishop; Kyla Shelton; Lu Lu; Sujuan Huang; Zhenghong Li; Eric Caron; Jennifer Lanctot; Carrie Howell; Timothy Folse; Vijaya Joshi; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Kevin R Krull; Tara M Brinkman; Raja B Khan; Deo K Srivastava; Melissa M Hudson; Yutaka Yasui; Leslie L Robison Journal: Lancet Date: 2017-09-08 Impact factor: 79.321
Authors: Fei Chen; Sungshim L Park; Lynne R Wilkens; Peggy Wan; Steven N Hart; Chunling Hu; Siddhartha Yadav; Fergus J Couch; David V Conti; Adam J de Smith; Christopher A Haiman Journal: Cancer Res Date: 2022-09-16 Impact factor: 13.312
Authors: Nan Song; Chia-Wei Hsu; Haitao Pan; Yinan Zheng; Lifang Hou; Jin-Ah Sim; Zhenghong Li; Heather Mulder; John Easton; Emily Walker; Geoffrey Neale; Carmen L Wilson; Kirsten K Ness; Kevin R Krull; Deo Kumar Srivastava; Yutaka Yasui; Jinghui Zhang; Melissa M Hudson; Leslie L Robison; I-Chan Huang; Zhaoming Wang Journal: Genome Med Date: 2021-04-06 Impact factor: 11.117
Authors: Jasmine H Francis; Allison L Richards; Diana L Mandelker; Michael F Berger; Michael F Walsh; Ira J Dunkel; Mark T A Donoghue; David H Abramson Journal: Cancers (Basel) Date: 2021-01-05 Impact factor: 6.639
Authors: Jung Kim; Matthew Gianferante; Danielle M Karyadi; Stephen W Hartley; Megan N Frone; Wen Luo; Leslie L Robison; Gregory T Armstrong; Smita Bhatia; Michael Dean; Meredith Yeager; Bin Zhu; Lei Song; Joshua N Sampson; Yutaka Yasui; Wendy M Leisenring; Seth A Brodie; Kelvin C de Andrade; Fernanda P Fortes; Alisa M Goldstein; Payal P Khincha; Mitchell J Machiela; Mary L McMaster; Michael L Nickerson; Leatrisse Oba; Alexander Pemov; Maisa Pinheiro; Melissa Rotunno; Karina Santiago; Talia Wegman-Ostrosky; W Ryan Diver; Lauren Teras; Neal D Freedman; Belynda D Hicks; Bin Zhu; Mingyi Wang; Kristine Jones; Amy A Hutchinson; Casey Dagnall; Sharon A Savage; Margaret A Tucker; Stephen J Chanock; Lindsay M Morton; Douglas R Stewart; Lisa Mirabello Journal: JNCI Cancer Spectr Date: 2021-01-23